LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1506

Search options

  1. Article: Streitgespräch: Hausarzt Dieter Wettig und Gesundheitswissenschaftler Jens Holst zur Praxisgebühr

    Wettig, Dieter / Holst, Jens

    Deutsches Ärzteblatt : Ausgabe A, Praxis, Ausgabe : niedergelassene Ärzte

    2008  Volume 105, Issue 13, Page(s) 659

    Language German
    Document type Article
    ZDB-ID 1453475-7
    ISSN 0012-1207
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.103/2: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Glucagon 100 years. Important, but still enigmatic.

    Holst, Jens Juul

    Peptides

    2023  Volume 161, Page(s) 170942

    Abstract: Glucagon was discovered in 1923 as a contaminant of early insulin preparations, and its hormonal status was not established until its structure was established in the 1950 s and when the first radioimmunoassay was developed by Roger Unger, providing ... ...

    Abstract Glucagon was discovered in 1923 as a contaminant of early insulin preparations, and its hormonal status was not established until its structure was established in the 1950 s and when the first radioimmunoassay was developed by Roger Unger, providing information about its secretion. Its role in hepatic glucose production was soon established and it was proposed as an essential factor in diabetic hyperglycemia. However, even today a number of issues remain unsolved. For instance, the assays for glucagon are not straightforward, although the development of sandwich ELISAs allowed reasonably accurate measurements also in rodents. The tools for evaluation of glucagon physiology include pancreatectomy, but studies in both humans and experimental animals pointed towards extrapancreatic sources of glucagon. It was demonstrated that glucagon receptor knockout animals do not develop diabetes upon destruction of their beta cells with streptozotocin. However, in patients with type 1 diabetes, glucagon antagonists do not normalize glucose levels; but antagonists do lower glucose levels in patients with in type 2 diabetes. Recent studies in animals and humans have confirmed the essential role of glucagon in glucose metabolism, but have suggested that it may be at least equally important for amino acid and lipid metabolism. In spite of the 100 years, glucagon research is very much alive.
    MeSH term(s) Animals ; Humans ; Blood Glucose/metabolism ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon/metabolism ; Glucose/metabolism ; Hyperglycemia/metabolism ; Insulin
    Chemical Substances Blood Glucose ; Glucagon (9007-92-5) ; Glucose (IY9XDZ35W2) ; Insulin
    Language English
    Publishing date 2023-01-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 769028-9
    ISSN 1873-5169 ; 0196-9781
    ISSN (online) 1873-5169
    ISSN 0196-9781
    DOI 10.1016/j.peptides.2023.170942
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1649: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Viral Neoliberalism: The Road to Herd Immunity Still A Rocky One.

    Holst, Jens

    International journal of health services : planning, administration, evaluation

    2022  , Page(s) 207314221131214

    Abstract: The objective of this article is to assess the dominant global economic system and the resulting power relations from the perspective of the strategies used worldwide against the SARS-CoV-2 pandemic. The predominantly biomedical approach has not ... ...

    Abstract The objective of this article is to assess the dominant global economic system and the resulting power relations from the perspective of the strategies used worldwide against the SARS-CoV-2 pandemic. The predominantly biomedical approach has not sufficiently taken into account the actual dimension of COVID-19 as a syndemic. While the much longer-term pandemic caused by the neoliberalism virus has not been systematically considered by public and global health scholars in the context of COVID-19, it exhibits essential characteristics of an infectious pathogen, and the symptoms can be described and detected according to biomedical criteria. Even more, the severity of leading symptoms of neoliberalism such as growing inequities calls for immunization campaigns and ultimately herd immunity from viral neoliberalism. However, achieving worldwide immunity would require an anti-neoliberal vaccine, which is extremely challenging to develop vis-à-vis the power relations in global health.
    Language English
    Publishing date 2022-10-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 184936-0
    ISSN 1541-4469 ; 0020-7314
    ISSN (online) 1541-4469
    ISSN 0020-7314
    DOI 10.1177/00207314221131214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 818: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Incretin-based therapy of metabolic disease.

    Holst, Jens Juul

    Danish medical journal

    2022  Volume 70, Issue 1

    Abstract: Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of ...

    Abstract Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.
    MeSH term(s) Humans ; Blood Glucose/metabolism ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Gastric Inhibitory Polypeptide/metabolism ; Glucagon-Like Peptide 1 ; Incretins/therapeutic use ; Metabolic Diseases/drug therapy ; Obesity/complications ; Obesity/drug therapy ; Weight Loss
    Chemical Substances Blood Glucose ; Gastric Inhibitory Polypeptide (59392-49-3) ; Glucagon-Like Peptide 1 (89750-14-1) ; Incretins
    Language English
    Publishing date 2022-12-21
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 2648771-8
    ISSN 2245-1919 ; 2245-1919
    ISSN (online) 2245-1919
    ISSN 2245-1919
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity.

    Holst, Jens Juul

    Frontiers in nutrition

    2022  Volume 9, Page(s) 964406

    Abstract: Because of differential processing of the hormone precursor, proglucagon, numerous peptide products are released from the pancreatic alpha cells and the intestinal L-cells in which the (pro)glucagon gene is expressed. Of particular interest in relation ... ...

    Abstract Because of differential processing of the hormone precursor, proglucagon, numerous peptide products are released from the pancreatic alpha cells and the intestinal L-cells in which the (pro)glucagon gene is expressed. Of particular interest in relation to obesity are glucagon from the pancreas and oxyntomodulin and GLP-1 from the gut, all of which inhibit food intake, but the other products are also briefly discussed, because knowledge about these is required for selection and evaluation of the methods for measurement of the hormones. The distal intestinal L-cells also secrete the appetite-inhibiting hormone PYY. Characteristics of the secretion of the pancreatic and intestinal products are described, and causes of the hypersecretion of glucagon in obesity and type 2 diabetes are discussed. In contrast, the secretion of the products of the L-cells is generally impaired in obesity, raising questions about their role in the development of obesity. It is concluded that the impairment probably is secondary to obesity, but the lower plasma levels may contribute to the development.
    Language English
    Publishing date 2022-08-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2776676-7
    ISSN 2296-861X
    ISSN 2296-861X
    DOI 10.3389/fnut.2022.964406
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Discovery of the GI Effects of GLP-1: An Historical Perspective.

    Holst, Jens Juul

    Digestive diseases and sciences

    2022  Volume 67, Issue 7, Page(s) 2716–2720

    Abstract: In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, ... ...

    Abstract In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, including gastric emptying rate, gastric acid secretion, and pancreatic enzyme secretion. The gut hormone is released in response to nutrient intake, and in further experiments, its release from the ileum paralleled inhibition of both gastric and pancreatic secretions. Based on these studies, it was concluded that GLP-1 is an important regulator of the so-called ileal brake, a term given for the observation that ileal perfusion of lipids delayed gastric emptying, reduced food intake, and induced satiety Welch et al. (1985), in addition to its functions as an incretin hormone. GLP-1 was subsequently identified as a physiological inhibitor of appetite and food intake, and based on these actions, the GLP-1 receptor agonists are today considered among the most powerful and effective antiobesity and antidiabetic agents available, with the added benefits of reducing the risk of the cardiovascular and renal complications associated with these conditions.
    MeSH term(s) Appetite ; Eating ; Gastrointestinal Hormones ; Glucagon-Like Peptide 1 ; Humans ; Hypoglycemic Agents ; Peptide Fragments/pharmacology
    Chemical Substances Gastrointestinal Hormones ; Hypoglycemic Agents ; Peptide Fragments ; Glucagon-Like Peptide 1 (89750-14-1)
    Language English
    Publishing date 2022-05-30
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-022-07519-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui V Zs.35: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?

    Holst, Jens J

    Journal of internal medicine

    2022  Volume 291, Issue 5, Page(s) 557–573

    Abstract: Glucagon-like peptide-1 (GLP-1) is a peptide derived from differential processing of the precursor for the hormone glucagon. It is secreted predominantly by endocrine cells in the gut epithelium in response to nutrient stimulation. Studies from the last ... ...

    Abstract Glucagon-like peptide-1 (GLP-1) is a peptide derived from differential processing of the precursor for the hormone glucagon. It is secreted predominantly by endocrine cells in the gut epithelium in response to nutrient stimulation. Studies from the last 35 years have given us an idea about its physiological functions. On the basis of some of its many actions, it has also been developed into a pharmaceutical agent for the treatment of obesity and type 2 diabetes (T2DM). It is currently positioned as the most effective anti-obesity agent available and is recommended in both national and international guidelines as an effective second-in line treatment for T2DM, in particular in patients with increased cardiovascular risk. In this review, I first discuss whether the processing of proglucagon may also result in GLP-1 formation in the pancreas and in glucagon in the gut. Next, I discuss the relationship between the physiological actions of GLP-1 and the therapeutic effects of the GLP-1 receptor agonists, which are far from being congruent and generally poorly understood. These relationships illustrate both the difficulties and the benefits of bridging results obtained in the laboratory with those emerging from the clinic.
    MeSH term(s) Diabetes Mellitus, Type 2/drug therapy ; Glucagon ; Glucagon-Like Peptide 1/physiology ; Glucagon-Like Peptide-1 Receptor ; Humans
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Glucagon-Like Peptide 1 (89750-14-1) ; Glucagon (9007-92-5)
    Language English
    Publishing date 2022-01-24
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 96274-0
    ISSN 1365-2796 ; 0954-6820
    ISSN (online) 1365-2796
    ISSN 0954-6820
    DOI 10.1111/joim.13433
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.44: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Book ; Online: Kostenbeteiligung für Patienten - Reformansatz ohne Evidenz!

    Holst, Jens

    theoretische Betrachtungen und empirische Befunde aus Industrieländern

    (Veröffentlichungsreihe der Forschungsgruppe Public Health ; 2008,305)

    2008  

    Author's details Jens Holst. Wissenschaftszentrum Berlin für Sozialforschung (WZB)
    Series title Veröffentlichungsreihe der Forschungsgruppe Public Health ; 2008,305
    Discussion paper / Wissenschaftszentrum für Sozialforschung, Forschungsschwerpunkt Bildung, Arbeit und Lebenschancen, Forschungsgruppe Public Health
    Collection Discussion paper / Wissenschaftszentrum für Sozialforschung, Forschungsschwerpunkt Bildung, Arbeit und Lebenschancen, Forschungsgruppe Public Health
    Subject code 610
    Language German
    Size 123 S. : graph. Darst.
    Edition Überarb. und aktualisierte Fassung des WZB discussion papers SP I 2007-304
    Publisher Wissenschaftszentrum Berlin für Sozialforschung (WZB)
    Publishing place Berlin
    Publishing country Germany
    Document type Book ; Online
    HBZ-ID HT017103725
    DOI 10.4126/38m-004399850
    Database Repository for Life Sciences

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Childhood Obesity at the Crossroads of Science and Social Justice.

    Ludwig, David S / Holst, Jens J

    JAMA

    2023  Volume 329, Issue 22, Page(s) 1909–1910

    MeSH term(s) Humans ; Child ; Pediatric Obesity/epidemiology ; Pediatric Obesity/prevention & control ; Social Justice
    Language English
    Publishing date 2023-05-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2023.7592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.88: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Book ; Conference proceedings: Extending social protection in health

    Holst, Jens

    developing countries' experiences, lessons learnt and recommendations ; International Conference on Social Health Insurance in Developing Countries Berlin, 05 - 07 December 2005

    2007  

    Institution Internationales Arbeitsamt
    Event/congress International Conference on Social Health Insurance in Developing Countries (2005, Berlin)
    Author's details International Labour Office ... [Comp. and ed. by Jens Holst ...]
    Keywords Entwicklungsländer ; Krankenversicherung ; Gesundheitsvorsorge ; Armut
    Subject Arme Leute ; Armer ; Besitzloser ; Verarmung ; Krankenversicherungsrecht
    Subject code 368.3820091724
    Language English
    Size 225 S.: Ill., graph. Darst., Kt.
    Publisher VAS, Verl. für Akad. Schriften
    Publishing place Frankfurt am Main
    Publishing country Germany
    Document type Book ; Conference proceedings
    Note Literaturangaben
    HBZ-ID HT015306615
    ISBN 978-3-88864-425-2 ; 3-88864-425-9
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2008 A 5289 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top